MXPA03011270A - Uso de antagonistas rank para tratar cancer. - Google Patents

Uso de antagonistas rank para tratar cancer.

Info

Publication number
MXPA03011270A
MXPA03011270A MXPA03011270A MXPA03011270A MXPA03011270A MX PA03011270 A MXPA03011270 A MX PA03011270A MX PA03011270 A MXPA03011270 A MX PA03011270A MX PA03011270 A MXPA03011270 A MX PA03011270A MX PA03011270 A MXPA03011270 A MX PA03011270A
Authority
MX
Mexico
Prior art keywords
treat cancer
rank antagonists
rank
antagonists
rankl
Prior art date
Application number
MXPA03011270A
Other languages
English (en)
Inventor
C Dougall William
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of MXPA03011270A publication Critical patent/MXPA03011270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan en la presente metodos para tratar cancer al administrar una cantidad eficaz de un agente que antagoniza la interaccion entre RANK y RANKL.
MXPA03011270A 2001-06-06 2002-06-05 Uso de antagonistas rank para tratar cancer. MXPA03011270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29667001P 2001-06-06 2001-06-06
PCT/US2002/017789 WO2002098362A2 (en) 2001-06-06 2002-06-05 Use of rank antagonists to treat cancer

Publications (1)

Publication Number Publication Date
MXPA03011270A true MXPA03011270A (es) 2004-03-18

Family

ID=23143011

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011270A MXPA03011270A (es) 2001-06-06 2002-06-05 Uso de antagonistas rank para tratar cancer.

Country Status (6)

Country Link
US (1) US20030021785A1 (es)
EP (1) EP1432438A2 (es)
JP (1) JP2005515159A (es)
CA (1) CA2449658A1 (es)
MX (1) MXPA03011270A (es)
WO (1) WO2002098362A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO128635A2 (ro) * 1997-04-16 2013-07-30 Amgen Inc. Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
ATE464068T1 (de) 2001-06-26 2010-04-15 Amgen Fremont Inc Antikörper gegen opgl
JP4761710B2 (ja) 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
WO2005028633A2 (en) * 2003-09-17 2005-03-31 Isis Pharmaceuticals, Inc. Modulation of rankl expression
PE20070684A1 (es) * 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
EP2433644A1 (en) * 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
FR2970870A1 (fr) * 2011-01-31 2012-08-03 Centre Nat Rech Scient Modulation de la proliferation des cellules epitheliales de l'unite epidermo-pilo-sebacee via rank
CA2831247C (en) * 2011-03-31 2020-07-21 Oriental Yeast Co., Ltd. Cancer immunopotentiating agent containing rankl antagonist
CA2854372A1 (en) 2011-11-07 2013-05-16 Universite Laval Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
CN105189551B (zh) * 2013-03-14 2021-03-05 埃派斯进有限公司 抗-rankl抗体及其使用方法
WO2015018421A1 (en) 2013-08-07 2015-02-12 Rigshospitalet Copenhagen University Hospital Antibodies, compounds and derivatives thereof for use in the treatment of male infertility

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US68690A (en) * 1867-09-10 bibge
US159970A (en) * 1875-02-16 Improvement in sickle-heads for harvesters
US127637A (en) * 1872-06-04 Improvement in couplings for divided axles
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
EP2371962A3 (en) * 1996-12-23 2011-12-21 Immunex Corporation Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
CA2349406C (en) * 1999-09-03 2011-01-11 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US6171860B1 (en) * 1999-11-05 2001-01-09 Isis Pharmaceuticals, Inc. Antisense inhibition of rank expression

Also Published As

Publication number Publication date
WO2002098362A3 (en) 2004-04-22
JP2005515159A (ja) 2005-05-26
US20030021785A1 (en) 2003-01-30
EP1432438A2 (en) 2004-06-30
CA2449658A1 (en) 2002-12-12
WO2002098362A2 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
WO2001023405A3 (en) Therapeutic treatment of androgen receptor driven conditions
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
EP1068870A4 (en) ANTITUMOR AGENTS
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
MY169308A (en) Treatment of tnf? related disorders
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
MXPA04002593A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
TW200519110A (en) Substituted tetrahydro-1H-pyrazolo [3, 4-c] pyridines, compositions comprising them, and use
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
AU2002357644A8 (en) Therapeutic agents and corresponding treatments
GB0308323D0 (en) Electromagnetic stimulation in patients with osteoporosis
MXPA03010406A (es) Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd.
MXPA03007653A (es) Uso de lp82 para tratar trastornos hematopoyeticos.
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
BR0111785A (pt) Composições e métodos para tratamento de candidìase
IL148336A0 (en) Medicaments that contain xenogenic oligo-or/and polyribonucleotides
DE602004012759D1 (de) Behandlung von fibrosen
WO2003004631A3 (en) USE OF INHIBITORS OF EXPRESSION OR ACTIVITY OF p8/com1 FOR TREATING TUMORS.